HPβCD treatment does not induce activation of apoptosis.
A, annexin V binding affinity change (%) in NCL2 patient-derived fibroblasts treated with HPβCD (0.1, 1, and 10 mm) or taxol (50 nm) for 1 day normalized to untreated cells (analysis of variance, p < 0.01). B, propidium iodide binding population change (%) of NCL2 patient-derived fibroblasts treated with HPβCD (0.1, 1, and 10 mm) or taxol (50 nm) for 1 day normalized to untreated cells (analysis of variance, p < 0.01). The number of total counted cells was 10,000. The data are reported as the mean ± S.D. (n ≥ 3).